Andere talen Neuronetics, Inc.

Aandelen

STIM

US64131A1051

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 01-12-2023			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,030 ^USD	+11,54%		+40,00%	-70,45%

13/11	Neuronetics, Inc. Verbetert depressiebehandeling met geavanceerde technologische vooruitgang	CI
07/11	Transcript : Neuronetics, Inc., Q3 2023 Earnings Call, Nov 07, 2023	CI

Andere talen

Ontgrendel al het nieuws: wees als eerste op de hoogte en reageer voordat de markten dat doen!

Gratis inschrijven

Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference	15/11
NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements	13/11
NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements	13/11
Neuronetics, Inc. Elevates Depression Treatment with Cutting-Edge Technology Advancements	13/11
Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage	09/11
Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage	09/11
Neuronetics: Q3 Earnings Snapshot	07/11
Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $17.9M	07/11
Neuronetics Reports Third Quarter 2023 Financial and Operating Results	07/11
Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023	07/11
Neuronetics Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	07/11
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	06/11
Neuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call	24/10
Neuronetics, Inc. - Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes	17/10
Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes	16/10
Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes	16/10
Neuronetics, Inc. Enters into Fifth Amendment to Loan and Security Agreement with SLR Investment Corp	03/10
Neuronetics Draws Down Remaining $22.5 Million From SLR Capital Credit Facility	03/10
Neuronetics Draws Down Remaining $22.5 Million Available Under Credit Facility	03/10

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel Artikel MarketScreener Analyse MarketScreener

Andere talen Neuronetics, Inc.

Aandelen

STIM

US64131A1051

Andere talen

Filters